MedTrace Logo

Study on Prescribers' Knowledge and Understanding of Safety Messages Following Dengvaxia® Product Information Update

NCT04170140 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2023-09-18

No results posted yet for this study

Summary

The primary objective of the study is to evaluate the effectiveness of additional risk minimization measures material by assessing the knowledge and understanding of healthcare professionals regarding the key safety messages provided in the material.

The secondary objective of the study is to evaluate if healthcare professionals know Dengvaxia product information, namely, age indication and contraindications.

Conditions

  • Dengue Virus Infection

Interventions

OTHER

No intervention

Questionnaire

Sponsors & Collaborators

  • Sanofi Pasteur, a Sanofi Company

    lead INDUSTRY

Principal Investigators

  • Clinical Sciences & Operations · Sanofi Pasteur, a Sanofi Company

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-01-07
Primary Completion
2020-03-05
Completion
2020-03-05

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04170140 on ClinicalTrials.gov